Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years

Added 554 days ago (18.12.2020)
Authors: Dana Horáková; Aaron Boster; Antonio Bertolotto; Mark S Freedman; Isabel Firmino*; Steven J Cavalier; Alan K Jacobs*; Karthinathan Thangavelu*; Nadia Daizadeh; Elizabeth M Poole*; Darren P Baker; David H Margolin*; Tjalf Ziemssen
Read article